AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EISAI CO., LTD. and EPIZYME, INC.Collaboration and License Agreement • March 16th, 2015 • Epizyme, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of the 12th day of March, 2015 (the “Restatement Date”) by and between Epizyme, Inc., a Delaware corporation having its principal place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139, U.S.A. (“EPIZYME”), and Eisai Co., Ltd., a Japan corporation, having its principal place of business at Koishikawa 4-6-10, Bunkyo-Ku, Tokyo 112-8088, Japan (“EISAI”). EPIZYME and EISAI are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
By Telefacsimile (81-3-3811-1459) With Follow Up by E-mail Eisai Co., Ltd. Attention: Chief Product Creation Officer Koishikawa 4-6-10 Bunkyo-Ku Tokyo 112-8088 JapanEpizyme, Inc. • March 16th, 2015 • Pharmaceutical preparations • New York
Reference is hereby made to (a) the Amended and Restated Collaboration and License Agreement dated as of March 12, 2015 (the “Amended and Restated Collaboration Agreement”), by and between Eisai Co., Ltd. (“Eisai”) and Epizyme, Inc. (“Epizyme”), (b) the Companion Diagnostics Agreement dated December 18, 2012, as amended by the First Amendment thereto dated May 31, 2013 (the “RMS Agreement”), by and between Epizyme and Eisai, on the one side, and RMS, on the other side and (c) the prior letter agreement dated December 21, 2012 (the “Prior Letter Agreement”), by and between Epizyme and Eisai, regarding the RMS Agreement.
